Single center experience with alpelisib-fulvestrant in heavily pretreated women with HR(+), HER-2 (-) metastatic breast cancer.

被引：0
|
作者：
Tryfonopoulos, Dimitrios
Tzouda, Vasiliki
Zouki, Dionysia
Kyriakidou, Athina
Sarris, Evangelos
Grivas, Anastasios
Gouveris, Panagiotis
Papaxoinis, George
Demiri, Stamatina G.
机构：
[1] St Savas AntiCanc Hosp, Athens, Greece
[2] Hosp Agios Savvas, Athens, Greece
[3] Agios Savvas Canc Hosp, Athens, Greece
[4] Agios Savvas Anticanc Hosp, Athens, Greece
[5] Agios Savvas Anticanc Hosp, Athens, CT, Greece
[6] Agios Savvas Anticanc Hosp, Dept Med Oncol 2, Athens, Greece
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e13034
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Response to fulvestrant in heavily pretreated postmenopausal women: a single-center experience
    Franco, S
    Perez, A
    Tan-Chiu, E
    Frankel, C
    Vogel, CL
    BREAST CANCER RESEARCH AND TREATMENT, 2004, 88 (02) : 103 - 108
  • [2] Response to fulvestrant in heavily pretreated postmenopausal women:a single-center experience
    Sandra Franco
    Alejandra Perez
    Elizabeth Tan-chiu
    Cynthia Frankel
    Charles L. Vogel
    Breast Cancer Research and Treatment, 2004, 88 : 103 - 108
  • [3] Fulvestrant (Faslodex®) demonstrates clinical benefit in heavily pretreated postmenopausal women with advanced breast cancer:: a single-center experience.
    Franco, S
    Perez, A
    Tan-Chiu, E
    Frankel, C
    Vogel, C
    BREAST CANCER RESEARCH AND TREATMENT, 2003, 82 : S105 - S105
  • [4] Fulvestrant in heavily pretreated postmenopausal women with advanced breast cancer
    Martinez Marin, Virginia
    Munoz Martin, Andres J.
    Vinuela Beneitez, M. Carmen
    Garcia Alfonso, Pilar
    Alonso Munoz, Antonio
    Perez Manga, Gumersindo
    MEDICINA CLINICA, 2009, 133 (10): : 371 - 374
  • [5] Clinical benefit of fulvestrant in heavily pretreated patients with metastatic breast cancer
    Scandurra, Giuseppa
    Carillio, Guido
    Aiello, Rosa Anna
    Chiarenza, Maurizio
    Mazzola, Antonella
    Ali, Marco
    Barone, Gloria
    Greco, Filippo
    Caruso, Michele
    ANNALS OF ONCOLOGY, 2007, 18 : 44 - 44
  • [6] Efficacy and safety of trastuzumab as a single agent in heavily pretreated patients with HER-2/NEU-overexpressing metastatic breast cancer
    Sawaki, M
    Ito, Y
    Tada, K
    Mizunuma, N
    Takahashi, S
    Horikoshi, N
    Kasumi, F
    Akiyama, F
    Sakamoto, G
    Imai, T
    Nakao, A
    Hatake, K
    TUMORI JOURNAL, 2004, 90 (01): : 40 - 43
  • [7] Efficacy and safety of palbociclib in heavily pretreated patients with HR+/HER2-metastatic breast cancer
    Ban, Marija
    Mise, Branka Petric
    Majic, Ana
    Drazic, Ivanka
    Vrdoljak, Eduard
    FUTURE ONCOLOGY, 2018, 14 (06) : 537 - 544
  • [8] Individualized administration of capecitabine plus lapatinib in heavily pretreated HER2+metastatic breast cancer patients: A single-center experience.
    Papaldo, P.
    Metro, G.
    Felici, A.
    Russillo, M.
    Pellegrini, D.
    Fabi, A.
    Ferretti, G.
    Introna, M.
    Cognetti, F.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [9] Clinical experience with fulvestrant in pretreated patients with advanced breast cancer.
    Menjon Beltran, S.
    Garcia Garcia, J., Sr.
    Gonzalez Flores, E.
    Conde Herrero, V.
    Gonzalez Jimenez, E., Sr.
    Gutierrez Lomas, V., Sr.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [10] Lapatinib-based therapy in heavily pretreated HER2-positive metastatic breast cancer: a single institution experience
    Crivellari, Diana
    Spazzapan, Simon
    Lombardi, Davide
    Militello, Loredana
    Torrisi, Elena
    Russo, Alessia E.
    Sorio, Roberto
    Talamini, Renato
    Miolo, Gianmaria
    Carli, Paolo
    Veronesi, Andrea
    TUMORI JOURNAL, 2012, 98 (01): : 33 - 38
12345